Sarah Cannon

TANDEM 2023 Calendar

Issue link: http://sarahcannon.uberflip.com/i/1492123

Contents of this Issue

Navigation

Page 2 of 3

0208/23SCB003/R6 In 2022, Sarah Cannon Research Institute (SCRI) formed a joint venture with US Oncology Research (USOR) to enhance clinical trial access and availability across the country. *Presentations highlighted in blue represent research that was conducted across SCRI and the Sarah Cannon Transplant & Cellular Therapy Network, a Network of nine FACT/ JACIE accredited transplant centers across HCA Healthcare. 3 THURSDAY, FEBRUARY 16 TH 5:45pm - 6:45pm Eastern Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title Author List *Legacy SCRI and Sarah Cannon Transplant & Cellular Therapy Network authors in blue, lead authors Bold *Legacy USOR authors in orange, lead authors Bold Session Name 5:45 - 6:45pm Poster LBA 14 Initial First-in-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT) and Tolerate Post-HCT Gemtuzumab Ozogamicin (GO) without Cytopenias Tomlinson B, Suh H, Koura D, Koehne G, Cho C, Bambace NM, Bernard L, Shah NN, Walter RB, DiPersio JF, Perales MA, Loken M, Nath S, Raffel G, Cooper B Poster Session: Late Breaking abstracts 5:45 - 6:45pm Poster LBA 22 Social Functioning after Transplantation and Cellular Therapy: Initial Patient- Reported Outcomes Results from the CIBMTR Cusatus R, Ndifon E, Mattila D, Berman L, Akinola I, Kapfhammer M, Jacox C, Luetke C, Hamilton BK, Muffly L, Negrin RS, Shaughnessy PJ, Shaw BE, Flynn KE Poster Session: Late Breaking abstracts 5:45 - 6:45pm Poster LBA 12 Rapcabtagene Autoleucel (YTB323), an Innovative CD19- Directed CAR-T Cell Therapy, Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Phase I Study Update Shah N, Flinn IW, Kwon M, Jaeger U, Briones J, Bachy E, Blaise D, Boissel N, Kato K, Riedell PA, Frigault MJ, Shune L, Teshima T, Ciceri F, Fleming S, Ferrari S, Pearson D, Whalen J, Yi L, Davis J, Masood A, Dickinson M, Barba P Poster Session: Late Breaking abstracts FRIDAY, FEBRUARY 17 TH 11:45am - 5:00pm Eastern Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title Author List *Legacy SCRI and Sarah Cannon Transplant & Cellular Therapy Network authors in blue, lead authors Bold *Legacy USOR authors in orange, lead authors Bold Session Name 11:45am - 1:00pm 11:45am - 1:00pm Magnolia 12 Oral NA Setting up a CART Cell Program in Resource-Limited Settings Berdeja JG Meet the Professor 6: Setting Up a CART Cell Program in Resource- limited Settings 3:45 - 5:15pm 5:00 - 5:15pm Royal Oral 54 Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity Oliai C, Hoeg RT, Pavlova A, Gandhi A, Muffly L, Mehta RS, Srour SA, Waller EK, Lowsky R, Patel SS, Dholaria B, Bachier CR, Pantin J, Salhotra A, McGuirk JP, Fernhoff NB, McClellan JS, Abedi M, Negrin RS, Meyer EH Oral Abstract - Session H: Late Effects and Relapse TANDEM TRANSPLANTATION AND CELLULAR THERAPY MEETINGS 2023 PRESENTATION CALENDAR

Articles in this issue

view archives of Sarah Cannon - TANDEM 2023 Calendar